@FierceBiotech: Does Alder's IPO setback signal that the biotech IPO boom is ending? Story | Follow @FierceBiotech
@JohnCFierce: 30% of preclin and PhI R&D devoted to cancer - Early-stage cancer drug pipeline booms as payers dig in for a fight. More | Follow @JohnCFierce
@DamianFierce: Second recent biotech buyout with a built-in CVR, after $FRX's $1.5B deal for $FURX. Article | Follow @DamianFierce
@EmilyMFierce: Glaxo, Sanofi stand ready to supply vaccines amid polio emergency. More from FierceVaccies | Follow @EmilyMFierce
> Flush from a record start to Sovaldi sales, Gilead ($GILD) says it will buy back $5 billion in shares. Story
> Investigators for Durham, NC-based Novan Therapeutics will present positive Phase II data for their experimental acne treatment. Release
> The ag-biotech Arcadia has raised $33 million in a Series D. Release
@FierceMedDev: Qiagen dials up sales as HPV competition heats up. Article | Follow @FierceMedDev
@VarunSaxena2: Braeburn Pharmaceuticals to clinically test subdermal implant for treatment of opioid dependence. Story via FierceDrugDelivery | Follow @VarunSaxena2
@EmilyWFierce: Biotronik scores FDA approval for MRI-safe pacemaker system. Story | Follow @EmilyWFierce
@MichaelGFierce: Icon's Verisome-delivered cataract inflammation treatment enters PhIII. Release | Follow @MichaelGFierce
> Siemens eyes an IPO to spin off its hearing business. More
> St. Jude's a-fib tech aces trial as FDA awaits. Item
Pharma News
@FiercePharma: Top read on FiercePharmaMarketing Weds: 10 big brands keep pumping out big bucks, with a little help from price hikes. Report | Follow @FiercePharma
@TracyStaton: Popular at FiercePharmaMarketing: Payers fret about the next drug doomsday: Pricey PCSK9 cholesterol meds. More | Follow @TracyStaton
@EricPFierce: CEO says Teva will close at least 11 plants, 15% of its network, and 16 more are being evaluated. Story | Follow @EricPFierce
@CarlyHFierce: Drug ads miss the mark with patients who need treatment the most. Article | Follow @CarlyHFierce
> Teva could kill 3 birds with one $6B deal for India's Cipla. More
> J&J, Roche, Celgene and others power new cancer-drug wave. Story
> Valeant sales rise on deals; Regeneron's Eylea falls short; Dendreon, Ariad aided by cost cuts. Report
> Big surprise: Payers don't trust pharma. The fix? Risky trials and transparency. Article
Pharma Manufacturing News
> B. Braun extends recall of saline solution. Story
> FDA to start dumping low-value drugs refused entry to the U.S. News
> FDA study of generic equivalency includes drug made at banned Wockhardt plant. Piece
> NECC owners agree to pay meningitis victims $70M, insurers kick in $25M. Article
> India pharma industry moves to restore its fallen reputation, flagging exports. More
Vaccines News
> Glaxo, Sanofi ready to supply vaccines amid polio emergency. More
> AstraZeneca merger could bring the vaccines heft Pfizer's been looking for. News
> Parents not always swayed to vaccinate children during disease outbreaks. Pierce
> Sanofi's Shan5 overcomes manufacturing setback to score thumbs up from WHO. Story
> Positive H7N9 data could help Novartis hawk flu vax business. Article